Equity Research firms currently have a positive stance on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.20. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $32.60 on a short term basis.
At the time of writing, the stock was trading at $24.59. This represents a change from the opening price of 0.37%. In terms of performance, year to date, the stock is -8.61%. The monthly stock performance comes in at 9.13%. For the quarter, shares are performing at 22.31%. Weekly performance analysis shows the equity at -2.15%.
In taking a look at technical levels, shares are trading 12.09% away from the 50 day simple moving average and 20.42% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -27.42% away from it’s 52- week high and 123.75% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Aclaris Therapeutics, Inc.’s RSI stands at 58.57. In looking at volatility levels, the shares saw weekly volatility of 3.70% and 4.36% over the past month.